Lead Product(s): GAD-alum
Therapeutic Area: Endocrinology Product Name: Diamyd
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 13, 2020
Diamyd Medical's Phase IIb trial DIAGNODE-2 with the diabetes vaccine Diamyd is expected to present Topline results at the end of September. All patients in the trial where Diamyd® is given directly into the lymph node have completed their 15-month visits according to plan.
Lead Product(s): Diamyd
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Protein Sciences Corporation
Deal Size: $5.0 million Upfront Cash: $5.0 million
Deal Type: Agreement February 05, 2020
The agreement facilitates the transition of the manufacturing process of recombinant GAD65, to a new manufacturer for future anticipated commercial manufacture.